Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human SYD985 in advanced or metastatic solid tumors
NL-OMON47853Phase 1Active, not recruiting
- Sponsor
- Synthon
- Start
- Oct 2014
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of trastuzumab duocarmazine in Nonhematologic neoplasms, breast cancer, gastric cancer (GC) and 3 more (2 arms), sponsored by Synthon. Primary endpoints: Dose-limiting toxicities, Adverse events and 1 more. Started Oct 2014; status: active, not recruiting.
02
Drugs
trastuzumab duocarmazine
03
Conditions
Nonhematologic neoplasmsbreast cancergastric cancer (GC)gastroesophageal junction adenocarcinomatransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON47853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47853.